HER2-Positive Breast Cancer | Striving for Consensus on the Optimal Management of HER2-Positive Breast Cancer

published 3 months ago by Dr Neil Love

Featuring a roundtable discussion with Drs Virginia F Borges, Sara Hurvitz and Ian E Krop, including the following topics: Introduction Impact of COVID-19 vaccinations on screening for breast cancer (0:00) Management of HER2-positive early breast cancer Case: A woman in her early 40s with ER/PR-positive, HER2-positive breast cancer achieves a pathologic complete response with docetaxel/trastuzumab/pertuzumab — Alan B Astrow, MD (6:30) Therapeutic approach for patients with HER2-positive breast cancer and residual disease after neoadjuvant therapy (10:04) Case: A woman in her early 70s with Grade III, ER/PR-negative, HER2-positive breast cancer develops shortness of breath after neoadjuvant chemotherapy — Dr Astrow (19:57) Disease-specific factors in the selection of neoadjuvant therapy for patients with HER2-positive breast cancer (28:00) Selection of HER2-targeted therapy in the adjuvant setting  (33:31) Selection and sequencing of therapies for HER2-positive metastatic breast cancer Case: A woman in her early 40s with HER2-positive breast cancer and brain metastases — Yanjun Ma, MD (36:11) Case: A woman in her mid-30s with ER/PR-positive, HER2-positive breast cancer and brain metastases — Estelamari Rodriguez, MD, MPH (40:56) Case: A woman in her mid-60s who presents with a large, ulcerated breast mass and is diagnosed with HER2-positive breast cancer and liver metastases — Dr Astrow (48:38) Choice of initial therapy for patients with metastatic HER2-positive breast cancer (55:08) Management of HER2-positive breast cancer with brain metastases; intracranial activity of tucatinib in patients with metastatic HER2-positive breast cancer (1:00:00) CNS penetration and intracranial response with the antibody-drug conjugates trastuzumab deruxtecan and T-DM1; efficacy and tolerability of neratinib after disease progression on tucatinib (1:07:28) Perspective on the use of hormonal therapy for patients with ER/PR-positive, HER2-positive breast cancer (1:12:45) Efficacy of PARP inhibitors in patients with HER2-positive breast cancer and BRCA mutations; emerging data from the OlympiA trial evaluating olaparib as adjuvant therapy for patients with HER2-negative breast cancer and germline BRCA mutations (1:18:53) Benefits and risks of the novel anti-HER2 antibody margetuximab for patients with HER2-positive advanced breast cancer (1:25:10) CME information and select publications

more episodes from Research To Practice | Oncology Videos